BACKGROUND: Current practice guidelines suggest routine use of several effective cardiac medications in hospital survivors of acute myocardial infarction (AMI). The objectives of our population-based study were to describe decade-long trends (1990-2001) in the use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, lipid-lowering agents, and combinations thereof, in patients discharged from all metropolitan Worcester (Mass) hospitals after AMI. METHODS: The study sample consisted of 5965 adult men and women of all ages discharged after AMI from all greater Worcester hospitals in 7 annual periods between 1990 and 2001. RESULTS: Although consistent increases in the use of each of the effective cardiac medications examined were observed over time, particularly marked relative increases in the use of angiotensin-converting enzyme inhibitors (168% relative increase) and lipid-lowering agents (1086% relative increase) were noted. Use of combinations of effective cardiac medications also increased substantially over time. Between 1990 and 2001, the percentage of hospital survivors treated with > or =3 cardiac medications increased from 12.9% to 74.0%. Advancing age, female sex, history of angina, hypertension, or heart failure during hospitalization, presence of an initial non-Q wave MI, and development of atrial fibrillation during the index hospitalization were independently associated with underuse of combination medical therapy. CONCLUSIONS: The present results suggest considerable improvements over the last decade in the medical management of patients hospitalized with AMI. Educational efforts, however, aimed at clinicians and designed to improve use of these therapies, as well as efforts to simplify medication regimens and enhance rates of adherence, remain warranted.
BACKGROUND: Current practice guidelines suggest routine use of several effective cardiac medications in hospital survivors of acute myocardial infarction (AMI). The objectives of our population-based study were to describe decade-long trends (1990-2001) in the use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, lipid-lowering agents, and combinations thereof, in patients discharged from all metropolitan Worcester (Mass) hospitals after AMI. METHODS: The study sample consisted of 5965 adult men and women of all ages discharged after AMI from all greater Worcester hospitals in 7 annual periods between 1990 and 2001. RESULTS: Although consistent increases in the use of each of the effective cardiac medications examined were observed over time, particularly marked relative increases in the use of angiotensin-converting enzyme inhibitors (168% relative increase) and lipid-lowering agents (1086% relative increase) were noted. Use of combinations of effective cardiac medications also increased substantially over time. Between 1990 and 2001, the percentage of hospital survivors treated with > or =3 cardiac medications increased from 12.9% to 74.0%. Advancing age, female sex, history of angina, hypertension, or heart failure during hospitalization, presence of an initial non-Q wave MI, and development of atrial fibrillation during the index hospitalization were independently associated with underuse of combination medical therapy. CONCLUSIONS: The present results suggest considerable improvements over the last decade in the medical management of patients hospitalized with AMI. Educational efforts, however, aimed at clinicians and designed to improve use of these therapies, as well as efforts to simplify medication regimens and enhance rates of adherence, remain warranted.
Authors: Raghavendra Charan P Makam; Nathaniel Erskine; David D McManus; Darleen Lessard; Joel M Gore; Jorge Yarzebski; Robert J Goldberg Journal: Am J Cardiol Date: 2016-09-13 Impact factor: 2.778
Authors: Jennifer G Robinson; Robert Wallace; Monika M Safford; Mary Pettinger; Barbara Cochrane; Marcia G Ko; Mary Jo O'Sullivan; Kamal Masaki; Helen Petrovich Journal: J Clin Lipidol Date: 2010 Jan-Feb Impact factor: 4.766
Authors: Jennifer Tjia; Jeroan Allison; Jane S Saczynski; Mayra Tisminetzky; Jane L Givens; Kate Lapane; Darleen Lessard; Robert J Goldberg Journal: Am J Med Date: 2013-07-05 Impact factor: 4.965
Authors: Jessica Hahn; Darleen Lessard; Jorge Yarzebski; Jordan Goldberg; Sean Pruell; Frederick A Spencer; Joel M Gore; Robert J Goldberg Journal: Am Heart J Date: 2007-04 Impact factor: 4.749
Authors: Murat Icen; Cynthia S Crowson; Marian T McEvoy; Frank J Dann; Sherine E Gabriel; Hilal Maradit Kremers Journal: J Am Acad Dermatol Date: 2009-03 Impact factor: 11.527
Authors: Jorge Yarzebski; Edgard Granillo; Frederick A Spencer; Darleen Lessard; Jerry H Gurwitz; Joel M Gore; Robert J Goldberg Journal: Int J Cardiol Date: 2008-01-16 Impact factor: 4.164
Authors: Jared Wasser; Robert J Goldberg; Frederick A Spencer; Jorge Yarzebski; Joel M Gore Journal: Coron Artery Dis Date: 2009-01 Impact factor: 1.439
Authors: Samuel W Joffe; Armen Chalian; Dennis A Tighe; Gerard P Aurigemma; Jorge Yarzebski; Joel M Gore; Darleen Lessard; Robert J Goldberg Journal: Am Heart J Date: 2009-08 Impact factor: 4.749